Development of a Bilayer Mutual Tablet of Candesartan and Pioglitazone for Diabetic-Hypertensive Patients

سال انتشار: 1402
محل انتشار: مجله علوم دارویی و شیمی، دوره: 6، شماره: 7
کد COI اختصاصی: JR_JMCH-6-7_005
زبان مقاله: انگلیسی
تعداد مشاهده: 240

نویسندگان

SRM College of Pharmacy, SRMIST, Kattankulathur, Chennai, Tamil Nadu-۶۰۳۲۰۳, India

چکیده

Background: Diabetes and hypertension are related illnesses that often coexist. Angiotensin receptor blockers like candesartan are typically used to treat Hypertension. A thiazolidinedione-type diabetes drug, pioglitazone helps those with type ۲ diabetes manage their elevated blood sugar levels. The absence of a combination dose form on the market today may have industrial implications. Regulatory bodies advocate the use of a Quality by Design (QbD) methodology during the product development process to ensure product quality.Objective: The current study strives to develop an oral bilayer matrix tablet of candesartan Cilexetil and pioglitazone increasing patient compliance and decreasing the frequency of doses for treating hypertensive cardiovascular damage.Method: Poloxamer ۴۰۷ was utilized as a polymer for immediate release. HPMC K۴M and EUDRAGIT RS ۱۰۰ for sustained release. Both layer blends were evaluated for precompression parameters. Using a ۳۲-factorial design, the influence of the variables like disintegration time and time required for ۱۰۰% drug release on Candesartan Cilexetil are measured.Results: The results show that HPMC forms a synergistic gel; controlling Pioglitazone medication release for ۲۰ hours. Batch F۶ with ۴۰ mg Eudragit produces a film around drug, limiting its release rate to ۲۴ hours. Candesartan Cilexetil immediate release layer demonstrated ۱۰۰% drug release at ۱۵ minutes.Conclusion: Quality by Design (QbD) approach offers an effective, efficient framework to incorporate Candesartan Cilexetil and Pioglitazone in a fixed dose bilayer tablet as this combo is beneficial for individuals who suffer from hypertension and type ۲ diabetes.

کلیدواژه ها

Candesartan Cilexetil, Croscarmellose, mutual release dosage form, Design expert, Pioglitazone, Poloxamer ۴۰۷

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.